Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

Abroad (travel likely)
RecruitingPHASE3

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Conditions

Acute Coronary Syndrome

Locations
  • Novartis Investigative Site, Clayton, Victoria, Australia
  • Novartis Investigative Site, Montreal, Quebec, Canada
  • Novartis Investigative Site, Luoyang, Henan, China
  • Novartis Investigative Site, Xuzhou, Jiangsu, China
  • Novartis Investigative Site, Nanchang, Jiangxi, China
  • Novartis Investigative Site, Wenzhou, Zhejiang, China
  • Novartis Investigative Site, Beijing, China
  • Novartis Investigative Site, Beijing, China
  • Novartis Investigative Site, Guangzhou, China
  • Novartis Investigative Site, Guangzhou, China
  • Novartis Investigative Site, Jining, China
  • Novartis Investigative Site, Shanghai, China
  • Novartis Investigative Site, Shanghai, China
  • Novartis Investigative Site, Tianjin, China
  • Novartis Investigative Site, Chambray-lès-Tours, France
  • Novartis Investigative Site, Montpellier, France
  • Novartis Investigative Site, Nantes, France
  • Novartis Investigative Site, Pessac, France
  • Novartis Investigative Site, Poitiers, France
  • Novartis Investigative Site, Leipzig, Saxony, Germany
  • Novartis Investigative Site, Hennigsdorf, Germany
  • Novartis Investigative Site, Kiel, Germany
  • Novartis Investigative Site, Hong Kong, Hong Kong, Hong Kong
  • Novartis Investigative Site, Pécs, Baranya, Hungary
  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary
  • Novartis Investigative Site, Budapest, Hungary
  • Novartis Investigative Site, Budapest, Hungary
  • Novartis Investigative Site, Miskolc, Hungary
  • Novartis Investigative Site, Belagavi, Karnataka, India
  • Novartis Investigative Site, Nashik, Maharashtra, India
  • Novartis Investigative Site, Bikaner, Rajasthan, India
  • Novartis Investigative Site, Chikushino-shi, Fukuka, Japan
  • Novartis Investigative Site, Kitakyushu, Fukuoka, Japan
  • Novartis Investigative Site, Kamakura, Kanagawa, Japan
  • Novartis Investigative Site, Sagamihara, Kanagawa, Japan
  • Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan
  • Novartis Investigative Site, Gdansk, Poland
  • Novartis Investigative Site, Opole, Poland
  • Novartis Investigative Site, Seoul, Seoul, South Korea
  • Novartis Investigative Site, Seoul, South Korea
  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain
  • Novartis Investigative Site, Huelva, Andalusia, Spain
  • Novartis Investigative Site, El Palmar, Murcia, Spain
  • Novartis Investigative Site, Las Palmas GC, Spain
  • Novartis Investigative Site, Madrid, Spain
  • Novartis Investigative Site, Madrid, Spain
  • Novartis Investigative Site, Salamanca, Spain
  • Novartis Investigative Site, Seville, Spain
  • Novartis Investigative Site, Valencia, Spain
  • Novartis Investigative Site, Bern, Switzerland
  • Novartis Investigative Site, Geneva, Switzerland
  • Novartis Investigative Site, Lucerne, Switzerland